Boston Scientific Vercise™ Deep Brain Stimulation System Receives CE Mark Approval for Treatment of Dystonia

Boston Scientific Vercise™ Deep BrainBoston Scientific Vercise™ Deep Brain Stimulation System Receives CE Mark Approval for Treatment of Dystonia PR Newswire NATICK, Massachusetts, November 19, 2013 First System To Selectively Stimulate Targeted Areas Of The Brain To Manage Symptoms of Debilitating Disease The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions. Dystonia affects more than 500,000 people across Europe, including children and adults. It is the third most common movement disorder after [1]Parkinson's disease and essential tremor. Symptoms include involuntary muscle contractions, with twisting, repetitive movements or abnormal postures, which can be painful and debilitating. The Vercise DBS System is the first system designed to selectively stimulate targeted areas of the brain in order to customize therapy and manage symptoms of Parkinson's disease. This system now offers new hope for patients with dystonia. The first implant of the Vercise DBS System for the treatment of dystonia was performed by a team from the Charité Campus Virchow-Klinikum (CVK), which included Prof. Dr. Andrea Kühn, Department of Neurology, and Dr. Gerd-Helge Schneider, Department of Functional Neurosurgery.